May 24, 2024 – Talk Bio

Minimal Weight Reduction Observed with Low Doses of New Zealand’s GLP-1/GLP-2 Agonist

11 months ago talkbio0Tagged Agonist, Body Weight, Dosage, Effect, GLP-1/GLP-2, Lowest, Minimal, New Zealand

New Zealand, GLP-1/GLP-2 agonist, weight reduction, lowest doses, minimal effect.

Merus’ Bispecific Antibody Therapy Shows Promising Early Results in Cancer Treatment

11 months ago talkbio0Tagged Antibodies, Bispecific, ASCO, Cancer Therapeutic Procedure, Expectations, investor, Merus

Merus, bispecific antibody, cancer treatment, early results, investor expectations, ASCO

Pharmaceutical Giants Secure Victory in Initial Zantac Lawsuit

11 months ago talkbio0Tagged Boehringer, Heartburn, Ingelheim, NDMA, ranitidine, SmithKline Beecham, victory, Zantac

Zantac, GSK, Boehringer Ingelheim, lawsuit, victory, heartburn medication, ranitidine, NDMA

Nuvation Bio Unveils Groundbreaking Cancer Drug Data from AnHeart Acquisition in China

11 months ago talkbio0Tagged Acquisition (action), AnHeart, Antineoplastic Agents, Bio, China, Clinical Trials, Nuvation

Nuvation Bio, AnHeart, cancer drug, pivotal data, China, acquisition, clinical trials

Revolutionizing Biotherapeutic Analysis: Novel icIEF Fractionation and Mass Spectrometry for Charge Characterization

11 months ago talkbio0Tagged analytical techniques, Biological Factors, biotherapeutics, Characterization, charge amounts, Chemical fractionation, Imaged Capillary Isoelectric Focusing, Protein Analysis, protein charge, Protein Purification, protein separation, therapeutic protein, Variant

biotherapeutics, icIEF fractionation, mass spectrometry, charge characterization, protein analysis, therapeutic proteins, biopharmaceuticals, analytical techniques, protein purification, protein separation, protein charge variants.

Semaglutide Significantly Improves Cardiovascular Health and Reduces Mortality Risk in Kidney Disease Patients, Novo Reports

11 months ago talkbio0Tagged Cardiovascular system, Clinical Trials, Health, Mortality Vital Statistics, Novo, semaglutide

Semaglutide, Novo, cardiovascular health, kidney disease, mortality risk, clinical trial

J&J Adjusts Dosing Strategy for Actinium Prostate Cancer Drug Following Early Study Setbacks

11 months ago talkbio0Tagged Actinium, Cancer Therapeutic Procedure, Cessation of life, Clinical Trials, dosing, Drug Development, Flexible, J&J, Johnson & Johnson, Malignant neoplasm of prostate

J&J, Johnson & Johnson, actinium prostate cancer drug, capped dosing, flexible dosing, patient deaths, early study, clinical trial, cancer treatment, drug development.